A relatively recent drug licensed for the treatment of PAH, riociguat belongs to a novel class of pharmacological agents that directly stimulate soluble guanylate cyclase (sGC), a key enzyme in the nitric oxide–cGMP signalling pathway, a major player in the pathophysiology of PAH. Here, SGCB is linked to pulmonary arterial hypertension.